

Refine Search

Search Results -

| Terms | Documents |
|-------------------------|-----------|
| melatonin same liposome | 10 |

Database:

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

L1

[Refine Search](#)[Recall Text](#)[Clear](#)[Interrupt](#)

Search History

DATE: Wednesday, March 16, 2005 [Printable Copy](#) [Create Case](#)

Set Name **Query**
side by side

Hit Count **Set Name**
result set

DB=USPT,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR

L1 melatonin same liposome

10 L1

END OF SEARCH HISTORY

[First Hit](#) [Fwd Refs](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L1: Entry 3 of 10

File: USPT

Nov 20, 2001

DOCUMENT-IDENTIFIER: US 6319517 B1

TITLE: Pharmaceutical preparation comprising lyophilized liposomes encapsulating an active principle which is highly insoluble in water, and the process for preparing the said preparation

Brief Summary Text (55):

Proceeding as described above, aqueous liposome compositions are obtained comprising about 8 mg/ml of melatonin, 3.8 mg/ml of lonidamine, 1 mg/ml of cyclosporin A and 4 mg/ml of bindarit against a water-solubility of 3.times.10.sup.-3 mg/ml (lonidamine), 1.times.10.sup.-1 mg/ml (bindarit) and, practically, the absolute insolubility of melatonin (G. S. Shida et al. "J. Pineal Res." 1994, 16, 198-201) and of cyclosporin A ["Insoluble in Water", a monograph of cyclosporin A in "Analytical Profiles of Drug Substances", 16, 163, (1987)].

Detailed Description Text (63):

Preparation III was lyophilized as described in Example 1 above, and the average size of the liposomes before and after lyophilization (Table 2/1), as well as the average size of the liposomes and the amount of melatonin in the fresh preparations and in those kept at 5.degree. C., were determined as described in the aforementioned example (Table 2/2).

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

[First Hit](#) [Fwd Refs](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L1: Entry 5 of 10

File: USPT

Apr 6, 1999

DOCUMENT-IDENTIFIER: US 5891465 A

TITLE: Delivery of biologically active material in a liposomal formulation for administration into the mouth

Detailed Description Text (34):

On the day of experimentation Baseline "0" melatonin levels were drawn. Two sprays of melatonin liposome spray formula was applied to sublingual area of the mouth. Saliva was allowed to accumulate for several minutes and then swallowed. Blood samples were drawn at 1/2 hour, 1 hour, 1 1/2 hours, 2 hours, 4 hours, 6 hours and 8 hours.

CLAIMS:

1. A liposomal composition suitable for the aerosol or spray delivery of melatonin to a subject, said composition comprising melatonin and optionally an additional supplement in phospholipid liposomes and a carrier wherein the liposomes have between about 20 nm and 10 microns in diameter and results in absorption into the blood stream, when administered, wherein the phospholipid liposome comprises one or more bilayer forming lipids, wherein said composition provides an increase in bioavailability of said supplement or drug of approximately 20 % or more when compared to an orally administered solid form, and wherein said composition comprises by weight percent, from about 0.25 to 20% lecithin, from about 0.025 to 2% cholesterol or zoosterol or phytosterol, from about 0.01 to 3% antioxidant, from about 0.05 to 0.4% melatonin, from about 0.1 to 20% glycerin, propylene glycol or butylene glycol, from about 0.1% to 10% ethanol, from about 0.015 to 4% anti microbial agent and from about 2 to 99.9% water.

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

[First Hit](#) [Fwd Refs](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L1: Entry 2 of 10

File: USPT

Jan 8, 2002

DOCUMENT-IDENTIFIER: US 6337087 B1

TITLE: Aqueous pharmaceutical composition comprising an active ingredient which is highly insoluble in water

Detailed Description Text (14):quantity of melatonin trapped in the liposomes.Detailed Description Paragraph Table (1):

Parameters Significance liposome size stability in the formulation time;
measurement of the "fusion" of the vesicles; melatonin amount concentration of
melatonin in the aqueous liposomal composition; stability in the formulation time;

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

[First Hit](#) [Previous Doc](#) [Next Doc](#) [Go to Doc#](#)
End of Result Set

☐ [Generate Collection](#) [Print](#)

L1: Entry 10 of 10

File: DWPI

Nov 20, 1997

DERWENT-ACC-NO: 1998-008557
DERWENT-WEEK: 200045
COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Liposomal formulation for administration as aerosol or liquid droplet spray
- for drug or nutritional supplement administration either orally or nasally

INVENTOR: FISHER, D L; KELLER, B C ; KISS, S

PATENT-ASSIGNEE: BIOZONE LAB INC (BIOZN)

PRIORITY-DATA: 1996US-0645894 (May 14, 1996)

[Search Selected](#)[Search ALL](#)[Clear](#)

PATENT-FAMILY:

| PUB-NO | PUB-DATE | LANGUAGE | PAGES | MAIN-IPC |
|--|-------------------|----------|-------|-------------|
| <input type="checkbox"/> WO 9742938 A1 | November 20, 1997 | E | 032 | A61K009/127 |
| <input type="checkbox"/> JP 2000510841 W | August 22, 2000 | | 028 | A61K009/127 |
| <input type="checkbox"/> US 5891465 A | April 6, 1999 | | 000 | A61K009/127 |
| <input type="checkbox"/> EP 928189 A1 | July 14, 1999 | E | 000 | A61K009/127 |

DESIGNATED-STATES: CA JP YU AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE AT
BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

APPLICATION-DATA:

| PUB-NO | APPL-DATE | APPL-NO | DESCRIPTOR |
|---------------|----------------|----------------|------------|
| WO 9742938A1 | April 21, 1997 | 1997WO-US06618 | |
| JP2000510841W | April 21, 1997 | 1997JP-0540877 | |
| JP2000510841W | April 21, 1997 | 1997WO-US06618 | |
| JP2000510841W | | WO 9742938 | Based on |
| US 5891465A | May 14, 1996 | 1996US-0645894 | |
| EP 928189A1 | April 21, 1997 | 1997EP-0921295 | |
| EP 928189A1 | April 21, 1997 | 1997WO-US06618 | |
| EP 928189A1 | | WO 9742938 | Based on |

INT-CL (IPC): [A61 K 9/12](#); [A61 K 9/127](#)

ABSTRACTED-PUB-NO: US 5891465A
BASIC-ABSTRACT:

Composition for administering an agent comprises an aerosol or spray for oral or nasal administration comprising the agent in a lipid encapsulated form.

The agent can be selected from, e.g. Ginkgo biloba extract, Kava extract, Ginseng extract, Saw Palmetto extract, glucosamine sulphate, chromium picolinate, Milk thistle extract, Grape seed extract, Ma Huang extract, melatonin, Echinacea, Co-Q10 supplement, water soluble vitamins, fat soluble vitamins and combinations thereof. Alternatively, the agent may be a drug. The lipid vesicle or liposome, encapsulating the agent, comprises one or more lipids selected from lecithin, ceramides, phosphatidylethanolamine, phosphatidylcholine, phosphatidylserine and cardiolipin. The liposomal preparation may contain different types of liposomes, e.g. small unilamellar vesicles, large unilamellar vesicles, multilamellar vesicles or oligolamellar vesicles.

USE - The composition is used for delivering an active agent orally or nasally. Active agents include nutritional supplements particularly herbs and plant extracts or drugs e.g. hormones, cardiovascular agents, antiarrhythmics, calcium channel blocking agents, vasopressors, beta -adrenergic blocking agents, antihypertensives, CNS stimulants, analgesics, antiemetic/antivertigo agents, antianxiety agents, antidepressants, antipsychotics, sedative hypnotics, anticonvulsants, muscle relaxants, anti-Parkinson agents, antimicrobial agents, antiviral agents and antibiotics. The agent is absorbed sublingually, particularly under the tongue and between the cheek and the gum or can be administered nasally for local or systemic action.

ADVANTAGE - The formulations provide bioavailability improved from approx. 20-50% when compared to an orally administered solid form.

ABSTRACTED-PUB-NO: WO 9742938A
EQUIVALENT-ABSTRACTS:

Composition for administering an agent comprises an aerosol or spray for oral or nasal administration comprising the agent in a lipid encapsulated form.

The agent can be selected from, e.g. Ginkgo biloba extract, Kava extract, Ginseng extract, Saw Palmetto extract, glucosamine sulphate, chromium picolinate, Milk thistle extract, Grape seed extract, Ma Huang extract, melatonin, Echinacea, Co-Q10 supplement, water soluble vitamins, fat soluble vitamins and combinations thereof. Alternatively, the agent may be a drug. The lipid vesicle or liposome, encapsulating the agent, comprises one or more lipids selected from lecithin, ceramides, phosphatidylethanolamine, phosphatidylcholine, phosphatidylserine and cardiolipin. The liposomal preparation may contain different types of liposomes, e.g. small unilamellar vesicles, large unilamellar vesicles, multilamellar vesicles or oligolamellar vesicles.

USE - The composition is used for delivering an active agent orally or nasally. Active agents include nutritional supplements particularly herbs and plant extracts or drugs e.g. hormones, cardiovascular agents, antiarrhythmics, calcium channel blocking agents, vasopressors, beta -adrenergic blocking agents, antihypertensives, CNS stimulants, analgesics, antiemetic/antivertigo agents, antianxiety agents, antidepressants, antipsychotics, sedative hypnotics, anticonvulsants, muscle relaxants, anti-Parkinson agents, antimicrobial agents, antiviral agents and antibiotics. The agent is absorbed sublingually, particularly under the tongue and between the cheek and the gum or can be administered nasally for local or systemic action.

ADVANTAGE - The formulations provide bioavailability improved from approx. 20-50% when compared to an orally administered solid form.

CHOSEN-DRAWING: Dwg.0/0

DERWENT-CLASS: B05 B07

CPI-CODES: B12-M01A; B12-M11F;

[Previous Doc](#)

[Next Doc](#)

[Go to Doc#](#)

Hit List

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Search Results - Record(s) 1 through 10 of 10 returned.☐ 1. Document ID: US 6635274 B1**Using default format because multiple data bases are involved.**

L1: Entry 1 of 10

File: USPT

Oct 21, 2003

US-PAT-NO: 6635274

DOCUMENT-IDENTIFIER: US 6635274 B1

TITLE: Solution-based transdermal drug delivery system

DATE-ISSUED: October 21, 2003

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|--------------------|-----------|-------|----------|---------|
| Masiz; John J. | Topsfield | MA | | |
| Carter; Stephen G. | Andover | MA | | |

US-CL-CURRENT: 424/449; 424/447

| Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWAC | Draw. De |
|------|-------|----------|-------|--------|----------------|------|-----------|--|--|--------|------|----------|
|------|-------|----------|-------|--------|----------------|------|-----------|--|--|--------|------|----------|

☐ 2. Document ID: US 6337087 B1

L1: Entry 2 of 10

File: USPT

Jan 8, 2002

US-PAT-NO: 6337087

DOCUMENT-IDENTIFIER: US 6337087 B1

TITLE: Aqueous pharmaceutical composition comprising an active ingredient which is highly insoluble in water

DATE-ISSUED: January 8, 2002

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---------------------|-----------------|-------|----------|---------|
| Cavallo; Giovanni | Ostia | | | IT |
| Marchitto; Leonardo | Cupra Marittima | | | IT |

US-CL-CURRENT: 424/450

| Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWAC | Draw. De |
|------|-------|----------|-------|--------|----------------|------|-----------|--|--|--------|------|----------|
|------|-------|----------|-------|--------|----------------|------|-----------|--|--|--------|------|----------|

☐ 3. Document ID: US 6319517 B1

L1: Entry 3 of 10

File: USPT

Nov 20, 2001

US-PAT-NO: 6319517

DOCUMENT-IDENTIFIER: US 6319517 B1

TITLE: Pharmaceutical preparation comprising lyophilized liposomes encapsulating an active principle which is highly insoluble in water, and the process for preparing the said preparation

DATE-ISSUED: November 20, 2001

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---------------------|-----------------|-------|----------|---------|
| Cavallo; Giovanni | Ostia | | | IT |
| Marchitto; Leonardo | Cupra Marittima | | | IT |

US-CL-CURRENT: 424/450; 264/4.1, 264/4.3, 424/1.21, 424/417, 424/9.321, 424/9.51, 514/2, 514/21, 514/8

| | | | | | | | | | | | | |
|------|-------|----------|-------|--------|----------------|------|-----------|--|--|--------|-----|--------|
| Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KMC | Draw D |
|------|-------|----------|-------|--------|----------------|------|-----------|--|--|--------|-----|--------|

☐ 4. Document ID: US 6075045 A

L1: Entry 4 of 10

File: USPT

Jun 13, 2000

US-PAT-NO: 6075045

DOCUMENT-IDENTIFIER: US 6075045 A

TITLE: Method of treating paralysis of the extremities caused by cerebral infarction

DATE-ISSUED: June 13, 2000

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|-----------------------|---------------|-------|----------|---------|
| Nishino; Hitoo | Nagoya | | | JP |
| Borlongan; Cesario V. | Silver Spring | MD | | |
| Uneyama; Hisayuki | Kawasaki | | | JP |

US-CL-CURRENT: 514/419

| | | | | | | | | | | | | |
|------|-------|----------|-------|--------|----------------|------|-----------|--|--|--------|-----|--------|
| Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KMC | Draw D |
|------|-------|----------|-------|--------|----------------|------|-----------|--|--|--------|-----|--------|

☐ 5. Document ID: US 5891465 A

L1: Entry 5 of 10

File: USPT

Apr 6, 1999

US-PAT-NO: 5891465

DOCUMENT-IDENTIFIER: US 5891465 A

TITLE: Delivery of biologically active material in a liposomal formulation for administration into the mouth

DATE-ISSUED: April 6, 1999

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|-------------------|---------------|-------|----------|---------|
| Keller; Brian C. | Antioch | CA | | |
| Fisher; Daniel L. | Pleasant Hill | CA | | |
| Kiss; Steven | Pittsburg | CA | | |

US-CL-CURRENT: 424/450; 424/43, 424/45, 424/727, 424/728, 424/734, 424/737, 424/766

| | | | | | | | | | | | | |
|------|-------|----------|-------|--------|----------------|------|-----------|--|--|--------|------|---------|
| Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWNC | Draw Ds |
|------|-------|----------|-------|--------|----------------|------|-----------|--|--|--------|------|---------|

☐ 6. Document ID: US 5716638 A

L1: Entry 6 of 10

File: USPT

Feb 10, 1998

US-PAT-NO: 5716638

DOCUMENT-IDENTIFIER: US 5716638 A

TITLE: Composition for applying active substances to or through the skin

DATE-ISSUED: February 10, 1998

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---------------|-----------|-------|----------|---------|
| Touitou; Elka | Jerusalem | | | IL |

US-CL-CURRENT: 424/450; 264/4.1, 264/4.3, 424/401, 424/63

| | | | | | | | | | | | | |
|------|-------|----------|-------|--------|----------------|------|-----------|--|--|--------|------|---------|
| Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWNC | Draw Ds |
|------|-------|----------|-------|--------|----------------|------|-----------|--|--|--------|------|---------|

☐ 7. Document ID: US 20010051652 A1

L1: Entry 7 of 10

File: DWPI

Dec 13, 2001

DERWENT-ACC-NO: 2002-146989

DERWENT-WEEK: 200219

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Use of melatonin for the treatment of paralysis of the extremities caused by cerebral infarction

INVENTOR: BORLONGAN, C V; NISHINO, H ; UNEYAMA, H

PRIORITY-DATA: 1999US-0300456 (April 28, 1999), 2000US-0563902 (May 4, 2000), 2001US-0754312 (January 5, 2001)

PATENT-FAMILY:

| PUB-NO | PUB-DATE | LANGUAGE | PAGES | MAIN-IPC |
|--------------------------|-------------------|----------|-------|------------|
| <u>US 20010051652 A1</u> | December 13, 2001 | | 006 | A61K031/40 |

INT-CL (IPC): A61 K 31/40

| Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw D |
|------|-------|----------|-------|--------|----------------|------|-----------|--|--|--------|------|--------|
|------|-------|----------|-------|--------|----------------|------|-----------|--|--|--------|------|--------|

8. Document ID: DE 69828394 E, WO 9836736 A1, ZA 9801352 A, AU 9864969 A, CZ 9902925 A3, EP 981332 A1, CN 1248163 A, SK 9901110 A3, HU 200001464 A2, IT 1289938 B, KR 2000075479 A, MX 9907684 A1, US 6319517 B1, JP 2001519776 W, AU 744115 B, SK 282931 B6, IL 131327 A, EP 981332 B1

L1: Entry 8 of 10

File: DWPI

Feb 3, 2005

DERWENT-ACC-NO: 1998-467265

DERWENT-WEEK: 200510

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Lyophilised composition - comprises trehalose and lipid liposome(s) including water insoluble biologically active component

INVENTOR: CAVALLO, G; MARCHITTO, L

PRIORITY-DATA: 1997IT-MI00362 (February 20, 1997)

PATENT-FAMILY:

| PUB-NO | PUB-DATE | LANGUAGE | PAGES | MAIN-IPC |
|------------------------|-------------------|----------|-------|-------------|
| <u>DE 69828394 E</u> | February 3, 2005 | | 000 | A61K009/127 |
| <u>WO 9836736 A1</u> | August 27, 1998 | E | 020 | A61K009/127 |
| <u>ZA 9801352 A</u> | October 28, 1998 | | 020 | A61K000/00 |
| <u>AU 9864969 A</u> | September 9, 1998 | | 000 | A61K009/127 |
| <u>CZ 9902925 A3</u> | January 12, 2000 | | 000 | A61K009/127 |
| <u>EP 981332 A1</u> | March 1, 2000 | E | 000 | A61K009/127 |
| <u>CN 1248163 A</u> | March 22, 2000 | | 000 | A61K009/127 |
| <u>SK 9901110 A3</u> | May 16, 2000 | | 000 | A61K009/127 |
| <u>HU 200001464 A2</u> | October 30, 2000 | | 000 | A61K009/127 |
| <u>IT 1289938 B</u> | October 19, 1998 | | 000 | A61K000/00 |
| <u>KR 2000075479 A</u> | December 15, 2000 | | 000 | A61K009/127 |
| <u>MX 9907684 A1</u> | June 1, 2000 | | 000 | A61K009/127 |
| <u>US 6319517 B1</u> | November 20, 2001 | | 000 | A61K009/127 |
| <u>JP 2001519776 W</u> | October 23, 2001 | | 020 | A61K009/127 |
| <u>AU 744115 B</u> | February 14, 2002 | | 000 | A61K009/127 |
| <u>SK 282931 B6</u> | January 9, 2003 | | 000 | A61K009/127 |
| <u>IL 131327 A</u> | July 25, 2004 | | 000 | A61K009/127 |
| <u>EP 981332 B1</u> | December 29, 2004 | E | 000 | A61K009/127 |

282931 B6 , IL 131327 A INT-CL (IPC): A61 K 0/00; A61 K 9/127; A61 K 9/19; A61 K 31/4045; A61 K 31/41; A61 K 31/416; A61 K 38/00; A61 K 38/13; A61 K 47/26; B01 F 0/00; B01 J 0/00

| Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWC | Draw D. |
|------|-------|----------|-------|--------|----------------|------|-----------|--|--|--------|-----|---------|
|------|-------|----------|-------|--------|----------------|------|-----------|--|--|--------|-----|---------|

9. Document ID: MX 217521 B, WO 9836735 A1, ZA 9801354 A, AU 9863987 A, CZ 9902926 A3, EP 973505 A1, SK 9901111 A3, CN 1255057 A, HU 200000910 A2, IT 1289939 B, KR 2000075480 A, MX 9907683 A1, AU 740619 B, JP 2001519775 W, US 6337087 B1, SK 282905 B6, EP 973505 B1, DE 69821001 E, ES 2213894 T3

L1: Entry 9 of 10

File: DWPI

Nov 12, 2003

DERWENT-ACC-NO: 1998-467264

DERWENT-WEEK: 200468

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Aqueous pharmaceutical compositions - comprise active ingredient highly insoluble in water, e.g. lonidamine, melatonin, cyclosporin A or bindarit, dispersed in liposomes

INVENTOR: CAVALLO, G; MARCHITTO, L

PRIORITY-DATA: 1997IT-MI00363 (February 20, 1997)

PATENT-FAMILY:

| PUB-NO | PUB-DATE | LANGUAGE | PAGES | MAIN-IPC |
|------------------------|-------------------|----------|-------|-------------|
| <u>MX 217521 B</u> | November 12, 2003 | | 000 | A61K009/127 |
| <u>WO 9836735 A1</u> | August 27, 1998 | E | 020 | A61K009/127 |
| <u>ZA 9801354 A</u> | October 28, 1998 | | 017 | A61K000/00 |
| <u>AU 9863987 A</u> | September 9, 1998 | | 000 | A61K009/127 |
| <u>CZ 9902926 A3</u> | January 12, 2000 | | 000 | A61K009/127 |
| <u>EP 973505 A1</u> | January 26, 2000 | E | 000 | A61K009/127 |
| <u>SK 9901111 A3</u> | June 12, 2000 | | 000 | A61K009/127 |
| <u>CN 1255057 A</u> | May 31, 2000 | | 000 | A61K009/127 |
| <u>HU 200000910 A2</u> | October 30, 2000 | | 000 | A61K009/127 |
| <u>IT 1289939 B</u> | October 19, 1998 | | 000 | A61K000/00 |
| <u>KR 2000075480 A</u> | December 15, 2000 | | 000 | A61K009/127 |
| <u>MX 9907683 A1</u> | June 1, 2000 | | 000 | A61K009/127 |
| <u>AU 740619 B</u> | November 8, 2001 | | 000 | A61K009/127 |
| <u>JP 2001519775 W</u> | October 23, 2001 | | 028 | A61K031/415 |
| <u>US 6337087 B1</u> | January 8, 2002 | | 000 | A61K009/127 |
| <u>SK 282905 B6</u> | January 9, 2003 | | 000 | A61K009/127 |
| <u>EP 973505 B1</u> | January 7, 2004 | E | 000 | A61K009/127 |
| <u>DE 69821001 E</u> | February 12, 2004 | | 000 | A61K009/127 |
| <u>ES 2213894 T3</u> | September 1, 2004 | | 000 | A61K009/127 |

B6 , EP 973505 B1 INT-CL (IPC): A61 K 0/00; A61 K 9/127; A61 K 31/192; A61 K 31/415; A61 K 31/416; A61 K 47/10; A61 K 47/12; A61 K 47/14; A61 K 47/24; A61 K 47/26; A61 P 15/08

| Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWC | Draw D. |
|------|-------|----------|-------|--------|----------------|------|-----------|--|--|--------|-----|---------|
|------|-------|----------|-------|--------|----------------|------|-----------|--|--|--------|-----|---------|

☐ 10. Document ID: WO 9742938 A1, JP 2000510841 W, US 5891465 A, EP 928189 A1

L1: Entry 10 of 10

File: DWPI

Nov 20, 1997

DERWENT-ACC-NO: 1998-008557

DERWENT-WEEK: 200045

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Liposomal formulation for administration as aerosol or liquid droplet spray
- for drug or nutritional supplement administration either orally or nasally

INVENTOR: FISHER, D L; KELLER, B C ; KISS, S

PRIORITY-DATA: 1996US-0645894 (May 14, 1996)

PATENT-FAMILY:

| PUB-NO | PUB-DATE | LANGUAGE | PAGES | MAIN-IPC |
|------------------------|-------------------|----------|-------|-------------|
| <u>WO 9742938 A1</u> | November 20, 1997 | E | 032 | A61K009/127 |
| <u>JP 2000510841 W</u> | August 22, 2000 | | 028 | A61K009/127 |
| <u>US 5891465 A</u> | April 6, 1999 | | 000 | A61K009/127 |
| <u>EP 928189 A1</u> | July 14, 1999 | E | 000 | A61K009/127 |

INT-CL (IPC): A61 K 9/12; A61 K 9/127

| | | | | | | | | | | | | |
|------|-------|----------|-------|--------|----------------|------|-----------|--|--|--------|------|----------|
| Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Drawn De |
|------|-------|----------|-------|--------|----------------|------|-----------|--|--|--------|------|----------|

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Terms

Documents

melatonin same liposome

10

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)